Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $0.42 per share a year ago.